Melinta Therapeutics Is A Biopharmaceutical Company Based In Parsippanynew Jerseyfocused On Developing Innovative Therapies For Acute And Life Threatening Bacterial Infectionsthe Company Specializes In Novel Anti Infectivesparticularly Antibiotics That Target Serious Bacterial Infectionsmelinta Is Committed To Patient Centric Innovation And Fosters A Culture Of Collaboration And Tenacity The Company S Marketed Products Include Baxdelaafor Acute Bacterial Skin Infectionsvabomereafor Complicated Urinary Tract Infectionsorbactivafor Acute Bacterial Skin Infectionsand Minocinafor Injectionmelinta Is Also Exploring Additional Uses For Delafloxacin And Advancing Other Candidates Like Meropenem Vaborbactam And Oritavancintheir Pipeline Utilizes A Ribosome Platform Licensed From Yale University To Develop New Mechanisms Against Antibiotic Resistant Pathogens Melinta S Revenue Includes Significant Contributions From International Marketsand The Company Is Dedicated To Addressing High Need Therapeutic Areaswith A Focus On Employee Growth And Open Communicationmelinta Aims To Expand Its Portfolio And Tackle Unmet Needs In Antibiotic Resistance
